To control disease before allogeneic hematopoietic cell transplantation (HCT) for relapsed/refractory AML, we used clofarabine cytoreduction. Seventeen patients received clofarabine 30-40 mg/m 2 i.v. daily for 5 days with plans to initiate conditioning during the nadir, 14 days later. Bone marrow biopsy 12 days after clofarabine showed effective cytoreduction (that is,o20% cellularity with o10% blasts) in 10 of 17 patients (59%). Ineffective cytoreduction correlated with lower PFS (3.8 vs 6.4 months; HR ¼ 2.7, 95% CI ¼ 1.10-14.29, P ¼ 0.035) and OS (5.1 vs 16.6 months; HR ¼ 2.5, 95% CI ¼ 0.98-12.17, P ¼ 0.053). Significant toxicities before HCT, attributable to clofarabine, were grade 1-2 hyperbilirubinemia (18%); grade 1-2 (59%) or grade 3-4 (18%) transaminitis; and grade 1-2 (18%) creatinine elevation. Sixteen patients proceeded to HCT infusion 22 days (median) after initiation of clofarabine. Day 100 and 2-year transplant-related mortality were 6 and 36%. Nine patients relapsed. One year PFS and OS were 25 and 38%, respectively. Two patients are alive in remission at 18 and 52 months. Clofarabine cytoreduction followed by immediate HCT is feasible with acceptable toxicity and TRM. Outcomes for this cohort of patients with refractory AML remain poor and we are studying this approach in a prospective manner.
Introduction
Patients with AML who do not achieve an initial complete remission following induction chemotherapy (primary refractory), or who relapse and are unable to achieve another remission following salvage chemotherapy (relapsed/refractory) have a very poor prognosis. 1 For these patients allogeneic hematopoetic stem cell transplantation (HCT) is the only treatment option with a reasonable potential for long-term disease control; however, only a minority of patients achieve durable remissions. 2, 3 Myeloablative HCT regimens are often recommended, but may be poorly tolerated. 4 Reduced intensity conditioning has fewer treatment-related complications, but is associated with even higher rates of recurrence in those with residual disease burden at the time of conditioning. 5, 6 Multiple strategies have been considered to improve outcomes for patients with relapsed/refractory disease. The HCT regimen may be re-intensified by adding agents with limited extramedullary and non-overlapping toxicities. Alternatively, post transplant manipulation has been attempted, such as immune modulation with donor lymphocyte infusions or anti-leukemic therapy with hypomethylating agents. 7 Lower disease burden before HCT strongly correlates with improved outcome; 5, 6, 8, 9 however, it is unknown if further cytotoxic salvage therapy before HCT improves outcomes or simply selects for chemosensitive patients. Prolonged pre-HCT treatment may lead to considerable toxicity and delay or eventually preclude HCT.
One approach to reduce disease burden uses the administration of re-induction therapy followed by HCT conditioning at the nadir of chemotherapy-induced aplasia. 10, 11 This cytoreductive chemotherapy 'bridge' has produced promising results in early studies for patients with newly diagnosed high-risk disease and relapsed patients with active disease. We have employed clofarabine salvage for this purpose and present results from 17 consecutive patients.
Materials and Methods

Patient selection and eligibility
For this retrospective review we included all AML patients with active disease who, before March 2008, received clofarabine 'bridge' with the intent of proceeding to HCT, whether or not this HCT occurred. In March 2008, a prospective study of this approach was initiated and patients participating in the prospective study are not included in this report. From an institutional pharmacy database we first identified patients who received clofarabine before March 2008, then excluded patients enrolled on an existing clofarabine, melphalan and alemtuzumab clinical trial 12 studying HCT conditioning for patients with hematological malignancies in remission (that is,: clofarabine not given as cytoreduction for active disease). We further selected those patients with AML, for whom a donor (related, unrelated, or cord) had been identified at the time of clofarabine initiation. Seventeen patients fit these criteria. Patients not fitting these criteria could not have received HCT at the hematologic nadir following clofarabine, for AML.
Clofarabine bridge and quantification of disease burden Clofarabine was given i.v. at a dose of 30-40 mg/m 2 daily for 5 days. Patients remained hospitalized following clofarabine induction. To determine response to clofarabine, bone marrow aspirate and biopsy were obtained before clofarabine administration and at the hematological nadir (around day 12) after clofarabine therapy, but before the initiation of transplant conditioning. We defined effective cytoreduction as a post clofarabine bone marrow cellularity of o20% and bone marrow blasts of o10%.
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Toxicity assessment
The electronic medical record was reviewed to grade toxicities after clofarabine according to NCI CTCAE v.3.
Transplant regimen
For patients proceeding to HCT, the preparative regimen was initiated during the hematological nadir, 14-21 days after clofarabine initiation. Patients with an adult donor (HLA) matched or mis-matched; related or unrelated) received one of the following previously described conditioning regimens (Table 1) (140 mg total) on day -3 and -2, and rATG 1.5 mg/kg i.v. (6 mg/kg total) on day -7, -5, -3, -1 (flu/mel/ ATG). Several cord blood units were supplemented with additional CD34 selected haplo-identical related adult peripheral blood stem cells. 16 Post transplant immunosuppression was tacrolimus from day À2 to day þ 100 for related adult donor recipients and until day þ 180 for unrelated adult donor recipients. For cord blood recipients, tacrolimus was given from day À1 to day þ 180 and mycophenolate mofetil from day À3 to day þ 28.
Statistical considerations
The primary end point was to assess the proportion of patients who achieved cytoreduction post clofarabine (at the nadir) as defined above; bone marrow o20% cellularity and bone marrow blasts o10%. Secondary end points were the tolerance to clofarabine and the ability to proceed to HCT as planned. Kaplan-Meier curves were stratified according to effective or ineffective cytoreduction, and compared by the log rank test. TRM was defined as death from any cause without evidence of relapse. Time to event analysis used the day of transplant as day 0. Descriptive statistics were employed to determine the proportion of toxicity associated with clofarabine (renal, hepatic, infectious or dermatological), to stratify patients by prognostic characteristics for comparison of overall survival (OS) and PFS, and to analyze engraftment and chimerism data. Neutrophil engraftment was defined as the first of 3 consecutive days with an ANC of Z0.5 k cells per microliter (ANC Z500). Complete donor chimerism was defined as 495% donor cells in both the unfractionated and CD3 compartments. a Two additional relapsed patients initially had primary refractory disease that responded to a previous allogeneic transplant. b All patients who were not refractory to the latest therapy (n ¼ 5) had relapsed after a previous stem cell transplant. c Induction or Salvage regimens, not including previous transplant.
Results
Patient characteristics
Patient characteristics are summarized in Table 1 . Of the 17 patients, four had therapy-related AML, two had antecedent MDS, with the remainder having de-novo disease. All patients had active refractory AML and extensive previous therapy. At the time of clofarabine induction, eight patients had a complex karyotype, two had 7q abnormalities, and two had a normal karyotype (one with known FLT3 mutation). A majority of patients (14 of 17) were refractory to the salvage regimen given before clofarabine, whereas the remainder (3 of 17) were in 2nd relapse following a previous transplant administered during 2nd remission (two allogeneic and one autologous transplant). Ten patients had primary induction failure and either never achieved remission (8 of 10), or had relapsed following an allogeneic transplant for primary induction failure (2 of 10). For the seven patients who achieved remission following initial induction chemotherapy, the median duration of CR1 was 9 months (range 6-15 months). Patients had received a median of 2.4 previous chemotherapy regimens.
Cytoreduction
The primary end point of effective cytoreduction was achieved in 59% (10 of 17) of patients. The median time to bone marrow biopsy from the first day of clofarabine administration was 12 days. The median marrow cellularity was 60% (range 4-90%, n ¼ 15) before and 5% (range 0-83%, n ¼ 17) at the nadir after clofarabine therapy. The marrow blast percentage declined from a median of 33% (range 10-100%, n ¼ 15) to 4% (range 0-90%, n ¼ 17) after clofarabine. The median absolute percentage change in bone marrow cellularity and blast percentage was 18% for both parameters. There was no statistically significant difference in pre-clofarabine marrow cellularity or blast percentage between patients effectively or ineffectively cytoreduced.
Clofarabine toxicity Renal, liver, skin and infectious toxicities after clofarabine administration, but before HCT infusion, are listed in Table 2 . Overall, 59% of patients experienced grade 1-2 and 18% grade 3-4 SGOT/SGPT elevations. Grade 1-2 hyperbilirubinemia was noted in three of 17 patients (18%). At the time of HCT infusion all liver function abnormalities had resolved to baseline with the exception of two patients (13%) who had persistent grade 1 toxicity. One patient experienced grade 4 bilirubin elevation, which peaked at the time of the patient's death 21 days after clofarabine was initiated. The attribution of this bilirubin elevation to clofarabine was unlikely because the patient had severe sepsis. Multi-organ failure prevented this patient from proceeding to a conditioning regimen or HCT. At no time did any patient develop clinical or pathological evidence of veno-occlusive disease.
Only three of 17 (18%) patients developed grade 1-2 creatinine elevation. Two of these patients had resolution of creatinine to baseline by the time of HCT. The third patient, who had a history of end stage renal disease and previous kidney transplant, developed creatinine elevation on the final day of clofarabine infusion. Shortly thereafter, the patient developed persistent Gram negative and enterococcal sepsis leading to death 17 days after HCT. Although the patient required hemodialysis and the creatinine never returned to baseline, the attribution of renal failure is unlikely to be secondary to clofarabine given the severe and overwhelming infection with multi-organ dysfunction leading directly to the patient's death.
Mild and reversible hand-foot skin toxicity (grade 1-2) was noted in only three of 17 patients (18%). No grade 3-4 skin events were recorded. Four of 17 (22%) patients experienced grade 3 mucositis. No patient required total parenteral nutrition within 2 weeks of administration of clofarabine. Two patients required total parenteral nutrition during their hospitalization due to malnutrition.
Thirteen of 17 (76%) patients had at least one episode of febrile neutropenia between the start of clofarabine administration and HCT infusion. Of these, six had an identified microbiological source, and three required intubation and medical intensive care unit transfer. Two of the three patients transferred to the medical intensive care unit died of their infectious complications as described above (one died without receiving HCT, the other died 17 days following HCT). The remaining four treatmentrelated deaths were associated with late infectious complications following transplant, rather than an immediate clofarabine toxicity. They include: one death 762 days after HCT from mucor pneumonia in the setting of chronic GVHD of the skin; one death 184 days after HCT due to disseminated aspergillosis, in a patient with a history of fungal pneumonia before HCT and chronic skin and gastrointestinal GVHD requiring chronic corticosteroid immunosuppression; one death 153 days after HCT from pulmonary complications in the setting of treated CMV Table 2 Toxicities following clofarabine and at the time of HCT pneumonia; and one death 104 days after HCT from sudden onset pulmonary edema after multiple infectious complications.
Results of HCT
Of the 17 patients, 16 proceeded to HCT infusion by day 26 after clofarabine (median and mean 22 days, range 17-26). Specific characteristics including relapse and survival details are provided in Table 3 . Day 100 TRM was 6% and 2-year TRM was 36%. Day 100 OS and PFS from the time of HCT were 81% (13 of 16) and 75% (12 of 16). One year Kaplan-Meier estimates were 25% for PFS and 38% for OS. Two year OS was 17%. Nine patients relapsed and all have died. Two patients are alive and in remission at 18 and 52 months post-HCT. PFS was 6.4 months (n ¼ 9) for patients who achieved effective cytoreduction with clofarabine, compared with 3.8 months (n ¼ 7) (HR ¼ 2.7, 95% CI ¼ 1.10-14.3, P ¼ 0.035) for those who did not achieve cytoreduction. OS was 16.6 months for patients who achieved cytoreduction compared with 5.1 months (HR ¼ 2.5, 95% CI ¼ 0.98-12.2, P ¼ 0.053) for patients who did not (Figure 1 ).
Engraftment and chimerism
The median duration of neutropenia from day 1 of clofarabine administration was 37 days (range 28-43). All patients achieved neutrophil engraftment by day 25 after HCT. The median time to neutrophil engraftment (40.5 Â 10 5 /ml) was 13 days (range 8-25 days) after HCT. Median time to platelet engraftment (420 Â 10 5 /ml) was 34 days with four patients having poor platelet recovery requiring repeated transfusions. Achievement of donor chimerism was similarly adequate. Among the 14 patients with evaluable chimerism data at day 30, 11 had complete donor chimersim (495%) in both the CD3 and unfractionated nucleated cell compartments. At day 100, seven of 11 evaluable patients had full donor chimerism.
Discussion
Relapsed/refractory AML has a dismal prognosis. Although HCT is generally the only curative option, active disease before HCT leads to limited survival, even among younger patients with a well-matched donor. 4, 17, 18 Longterm PFS for young patients undergoing fully myeloablative regimens approaches 25% at 3 years and with reduced intensity conditioning regimens is less than 10% at 5 years. 4, 18 One strategy to reduce the amount of disease at transplant and potentially improve outcomes is the use of pre-conditioning intensification with an active agent that has non-overlapping toxicities to the conditioning regimen. The feasibility of this strategy has been shown prospectively, both as initial therapy for patients with high-risk disease and for refractory patients with active disease. 10, 11 We have given clofarabine with the intent to reduce disease burden immediately before HCT for AML. Clofarabine has significant activity in relapsed leukemia with low morbidity and mortality in the elderly. 19 In addition, it may have less cross resistance in heavily pretreated patients and can achieve cytoreduction effectively and quickly, with peripheral blast clearance by 5 days. 20 Here, we present a retrospective examination of 17 relapsed/refractory AML patients having suitable allografts. This cohort was extremely high risk due to refractory, active AML (median marrow blasts of 33% pre-clofarabine), advanced age (median age 58 years), and with many lacking HLA identical siblings (56% MUD, MMUD or cord hematopoietic source). At the time of clofarabine therapy, all patients either were refractory to the last previous chemotherapy regimen given, or had active disease at relapse following a previous stem cell transplantation.
The goals of this retrospective analysis were to evaluate whether clofarabine could result in significant cytoreduction, measured at the hematologic nadir, and to determine if clofarabine administration affected the ability to complete and tolerate HCT.
Currently, no consensus exists for evaluation and stratification of disease burden at the hematological nadir after chemotherapy. It has been established that early blast clearance, defined as bone marrow blasts o10% at the hematological nadir after initial induction, is prognostic for achievement of CR and improved long-term outcomes. Furthermore, when evaluating patients after induction, persistent disease at the nadir is often used as the determinant of whether additional cytoreduction is necessary. 13 We used this important measure of early treatment response, along with achievement of bone marrow cellularity of o20%, to define effective cytoreduction at the nadir after clofarabine therapy. Thus defined, effective cytoreduction was achieved in 10 of 17 patients, an acceptable response rate in patients with advanced refractory AML.
Clofarabine cytoreduction before HCT conditioning at the nadir is feasible in terms of acceptable toxicities and donor chimerism: 16 of 17 patients proceeded to transplant and complete donor chimerism was achieved in 11 of 14 evaluable patients at 30 days. One of the 16 patients died of infectious complications 17 days after transplant. Infection related to febrile neutropenia (76%) was the most common toxicity following clofarabine and before HCT infusion. Clofarabine has known hepatic toxicities. 21 Mild and reversible hyperbiliribunemia and transaminase elevations were common, occurring in 24 and 81% of patients respectively. Of these, only two patients did not fully recover bilirubin and transaminases to baseline before HCT infusion. No patients developed clinical or pathological evidence of veno-occlusive disease after transplant. Renal insufficiency was observed in three patients, one of whom required hemodialysis. Although unlikely, the clofarabine may have precipitated renal failure and we advocate caution in patients with underlying renal dysfunction. Two-year TRM of patients following HCT was 36%, but the majority of deaths were attributed to late transplantrelated complications including infections and GVHD. Median PFS (5.3 months), OS (6.6 months), and 2-year OS (17%) in our retrospective case series are similar to outcomes of patients with active AML (420% blasts) from larger retrospective series where a bridging chemotherapy approach was not used. Importantly, however, idic(Xq),r (7) idic(Xq), r (7) PIF - patients achieving effective cytoreduction fared significantly better than those that did not (PFS 6.4 compared with 3.8 months, Po0.05; and OS 16.6 compared with 5.1 months, P ¼ 0.05). It has been established that active disease at HCT leads to dismal outcomes. 5, 8, 22 Previously our group has reported that for each 10% increase in marrow blast percentage at the time of HCT, there is an increased risk of death by a factor of 1.21. 6 Here, we present preliminary evidence that success at reduction of disease burden holds potential as an important prognostic marker and might impact outcome. The small number of patients studied and the retrospective nature of this analysis precludes definitive conclusions about the potential antileukemia efficacy of the clofarabine 'bridge'.
Conclusions and future directions
Clofarabine cytoreduction followed by allogeneic transplant at the hematological nadir was tolerated by very highrisk AML patients, however, its use in this setting needs to be studied in a prospective fashion with a focus on less heavily pre-treated patients. Clofarabine achieved cytoreduction in 59% (10 of 17) of patients with highly resistant AML. OS outcome for the entire group was poor. Achievement of effective cytoreduction may identify patients more likely to benefit from transplant, although even in this group there is considerable room for further outcome improvement. Owing to poor outcomes in patients not achieving cytoreduction, consideration should be made for a full intensity myeloablative regimen, investigational studies or best supportive care. To follow-up on these observations, we are currently conducting a prospective study for patients with advanced MDS or refractory leukemia, using clofarabine as a cytoreductive bridge to allogeneic stem cell transplant at the hematological nadir. clofarabine cytoreduction. Kaplan-Meier survival curves stratified by effective cytoreduction (dashed line) and ineffective cytoreduction (solid line). Effective cytoreduction was defined as a bone marrow cellularity o20% and blast% o10% measured 12 days after clofarabine administration. When comparing effective to ineffective cytoreduction (a) progression-free survival was 6.4 months (n ¼ 9) compared with 3.8 months (n ¼ 7) (HR ¼ 2.7, 95% CI ¼ 1.10-14.29, P ¼ 0.035) and (b) overall survival was 16.6 months compared with 5.1 months (HR ¼ 2.5, 95% CI ¼ 0.98-12.17, P ¼ 0.053).
